MAPK3 and malignant colon neoplasm: Other drugs targeting MAPK such as ERK1/2 inhibitor ulixertinib have also shown potent activity in clinical trials including colon cancer, gallbladder adenocarcinoma, glioblastoma and other solid tumors 62.